Separately, upon receipt of the full efficacy and safety results for the NORSE EIGHT clinical trial in the United States, which are expected in January 2025, Outlook Therapeutics plans to resubmit its ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

By Dr. Chinta Sidharthan A single injection of the therapeutic candidate was associated with improvements in maternal blood ...

Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to curr ...

Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to currently available Vabysmo vialsVabysmo has demonstrated rapid and robust vi ...

Transportation noise poses serious risks to cardiovascular health, causing inflammation, oxidative stress, and circadian ...

The drug candidate is administered through the intravitreal route. It is a soluble fusion protein comprising of vascular endothelial growth factor receptor 3 (VEGFR-3) fused to the Fc fragment of ...

Many eye conditions can be easily treated if those at risk undergo regular eye examinations, and are informed about good ...

Blood levels of two markers may help predict treatment response and outcomes in pulmonary arterial hypertension patients, per ...

Hope for a much-needed treatment for the common pregnancy complication pre-eclampsia has been raised by a successful test of ...

A new mRNA therapy tested in mice may target the root cause of the potentially fatal pregnancy disorder preeclampsia. It's ...